Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02312180 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency
A Phase 1 study, sponsored by Prometic Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02312180 is a Phase 1 study that has completed, run by Prometic Biotherapeutics. The registered enrollment target is 7 participants.
The verdict
NCT02312180, a Phase 1 study, has completed, sponsored by Prometic Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
ProMetic is intiitating a first-in-man study entitled "A Phase 1, Dose Escalation, and Pharmacokinetic Study of ProMetic Plasminogen Administered as Intravenous Infusion in Adults and Children with Hypoplasminogenemia". The general objectives of this clinical study, (Protocol #2002C005G), are to determine the optimal dose and interval required to support the planned Phase 2/3 study and to investigate initial safety and tolerability.
Interventions
- BIOLOGICAL Plasminogen (Human) Intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02312180
The ClinicalTrials.gov registry entry for NCT02312180 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prometic Biotherapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plasminogen (Human) Intravenous is the first listed.
NCT02312180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02312180 about?
NCT02312180 is a clinical study titled "A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency". ProMetic is intiitating a first-in-man study entitled "A Phase 1, Dose Escalation, and Pharmacokinetic Study of ProMetic Plasminogen Administered as Intravenous Infusion in Adults and Children with Hypoplasminogenemia". The general objectives of this clinical study, (Protocol #2002C005G), are to det...
What is the current status of trial NCT02312180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2014-12. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02312180?
The interventions under investigation include: Plasminogen (Human) Intravenous (BIOLOGICAL).
Who is sponsoring clinical trial NCT02312180?
This trial is sponsored by Prometic Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.